BioSpace News Archive

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three virtual investor conferences in June 2021.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, today announced it will host an Oncology R&D Day for analysts, investors, and the scientific community from 8:00 – 10:00 AM ET on Wednesday, June 16 th .

Century Therapeutics , a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Alessandro Riva , M.D., and Kimberly Blackwell, M.D., as new Independent Directors.

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced important findings from a podium presentation on DSUVIA

Financing led by EcoR1 Capital with additional new investor, Boxer Capital Strategic collaboration with co-founder, Schrödinger, Inc., to develop pipeline of selectively targeted therapeutics Founding scientists are world leaders in hematologic malignancies, genetics and structural biology

Echosens , a high-technology company offering the FibroScan family of products, announces the publication of a peer-reviewed article reporting the findings of an independent assessment conducted by Santa Barbara Actuaries Inc. (SBA) to evaluate from the payer’s perspective the cost effectiveness of deploying VCTE / CAP machines (FibroScan) for detecting and monitoring fatty liver disease (FLD).

TRxADE HEALTH, INC., a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., announced that its Board of Directors has authorized the repurchase of up to a maximum of $1.0 million of shares of the Company’s common stock.

Napo EU S.p.A., the Italian subsidiary of Napo Pharmacuticals, Inc., which is a wholly owned subsidiary of Jaguar Health, Inc., provided updates on plans to pursue conditional marketing authorization from the European Medicines Agency for crofelemer, the Company’s novel proprietary drug.

Splashblocker, LLC has been awarded a group purchasing agreement with Premier, Inc. effective June 1, 2021.

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 3:30 p.m. ET.